
Aignostics
Founded Year
2018Stage
Series B | AliveTotal Raised
$53.94MLast Raised
$34M | 1 yr agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+12 points in the past 30 days
About Aignostics
Aignostics specializes in AI-powered precision medicine, focusing on the biopharmaceutical industry. The company offers insights by analyzing complex biomedical data, including histopathology, omics, and clinical outcomes, to support drug development and improve patient outcomes. It serves the biopharma sector with solutions for target identification, translational research, trials, and companion diagnostics. It was founded in 2018 and is based in Berlin, Germany.
Loading...
Aignostics's Product Videos
ESPs containing Aignostics
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The digital pathology for general diagnostics market refers to the use of digital imaging technology and computational tools to analyze and interpret pathology specimens for diagnostic purposes. Instead of using traditional glass slides, digital pathology involves digitizing tissue samples and creating high-resolution images that can be viewed and analyzed on computer screens. These digital images…
Aignostics named as Highflier among 15 other companies, including Philips, Proscia, and Ibex.
Aignostics's Products & Differentiators
R&D
Identify and test novel biomarker / therapy combinations with pharma and biotech, as well as our academic partners.
Loading...
Research containing Aignostics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Aignostics in 6 CB Insights research briefs, most recently on Sep 19, 2025.

Sep 19, 2025 report
Book of Scouting Reports: AI Drug Discovery
Aug 7, 2025
The top 50 venture investors in Germany
May 23, 2025
The AI in drug R&D market map
Expert Collections containing Aignostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aignostics is included in 6 Expert Collections, including Artificial Intelligence (AI).
Artificial Intelligence (AI)
16,627 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health
12,122 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
571 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Generative AI
2,951 items
Companies working on generative AI applications and infrastructure.
Digital Health 50
50 items
AI in drug discovery
528 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Aignostics Patents
Aignostics has filed 2 patents.
The 3 most popular patent topics include:
- machine learning
- anatomical pathology
- artificial neural networks

Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/17/2023 | 9/10/2024 | Staining, Artificial neural networks, Histopathology, Machine learning, Anatomical pathology | Grant |
Application Date | 11/17/2023 |
|---|---|
Grant Date | 9/10/2024 |
Title | |
Related Topics | Staining, Artificial neural networks, Histopathology, Machine learning, Anatomical pathology |
Status | Grant |
Latest Aignostics News
Nov 6, 2025
The global AI-Powered Pathology Market is projected to grow significantly in the coming years. It was valued at USD 184 Million in 2023 and is forecast to reach USD 382 Million by 2030, representing a robust compound annual growth rate (CAGR) of 11.7% during 2024–2030. Get Free Sample Report: https://reports.valuates.com/request/sample/QYRE-Auto-33C18563/Global_AI_Powered_Pathology_Market?utm_source=prnewswire&utm_medium=referral&utm_campaign=ai_powered_pathology_market What are the key factors driving the growth of the AI-Powered Pathology Market? AI slide analysis is accelerating diagnostics by improving image interpretation speed and accuracy. Integration with genomics is advancing precision medicine through multimodal data insights. Regulatory approvals are boosting clinical adoption of AI pathology tools. Cloud platforms and big data are enhancing model accuracy and scalability. Rising demand for efficiency and personalization is driving investments in AI diagnostics. Source from Valuates Reports: https://reports.valuates.com/market-reports/QYRE-Auto-33C18563/global-ai-powered-pathology?utm_source=prnewswire&utm_medium=referral&utm_campaign=ai_powered_pathology_market TRENDS INFLUENCING THE GROWTH OF THE AI-POWERED PATHOLOGY MARKET: The integration of AI tools for digital slide analysis is revolutionizing the way pathologists process and interpret whole-slide images. Advanced image recognition algorithms enable faster and more accurate detection of abnormalities in tissue samples, improving diagnostic efficiency and reducing human error. These tools are being increasingly deployed in hospitals and diagnostic centers to automate repetitive tasks such as cell segmentation, feature extraction, and tumor grading. As laboratories transition toward digital pathology platforms, AI-powered slide analysis solutions are becoming a cornerstone of modern diagnostic workflows, driving rapid adoption across clinical and research environments. AI is enabling a convergence between pathology, genomics, and clinical data, allowing for multimodal diagnostic models that deliver comprehensive insights into disease biology. By combining histopathological images with molecular profiles and patient data, these systems can identify correlations that inform treatment decisions and therapeutic targets. The growing emphasis on personalized medicine is amplifying this trend, as healthcare providers seek tools that connect morphological and genomic information for more accurate prognostic assessments. This integration is expected to significantly enhance the predictive power of diagnostic systems and open new frontiers in cancer and rare-disease analysis. An increasing number of AI pathology solutions are receiving regulatory clearances from health authorities, paving the way for their use in clinical settings. These approvals validate the safety and efficacy of AI tools for diagnostic purposes, boosting confidence among healthcare providers and investors alike. As regulatory frameworks mature, vendors are focusing on developing explainable and transparent AI systems that comply with clinical governance standards. The rising number of approved AI algorithms is expected to fuel large-scale deployment in pathology labs worldwide, supporting the shift from pilot projects to routine clinical use. The proliferation of cloud computing and data-sharing infrastructures is enabling the creation of vast, high-quality annotated datasets that are essential for AI model training. These datasets enhance the precision of deep learning algorithms, allowing them to recognize complex tissue patterns and rare disease features with higher reliability. Cloud-based pathology platforms also facilitate remote collaboration, enabling pathologists and researchers to access and analyze slides from anywhere in real time. The growing ecosystem of interoperable cloud solutions is therefore a critical driver for scalable, cost-efficient AI model deployment across healthcare networks. Healthcare systems worldwide are under pressure to deliver personalized, high-quality care while optimizing operational efficiency. AI-powered pathology addresses both objectives by offering rapid, standardized, and data-driven diagnostics that improve patient outcomes. Hospitals, diagnostic centers, and research institutes are investing in AI tools to handle rising case volumes, reduce turnaround times, and improve resource utilization. This dual focus on clinical accuracy and productivity is accelerating the adoption of AI in pathology, positioning the technology as a key enabler of next-generation precision healthcare. Claim Yours Now! https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-33C18563&lic=single-user Which type segment is growing the fastest in the AI-Powered Pathology Market? Predictive Modeling – Fastest Growth AI-based predictive modeling tools—used for applications such as cancer prognostics and treatment response prediction—are the fastest-growing segment. These systems apply machine learning to large-scale histopathology datasets to forecast disease outcomes. Growth in this segment is propelled by the increasing focus on personalized medicine and patient-specific risk stratification. Although it currently represents a smaller share than image-analysis tools, predictive modeling is expanding at the highest rate. Disease Classification – Rapid Growth AI algorithms designed for disease classification from tissue images are also witnessing strong growth. These tools enhance diagnostic accuracy by distinguishing between benign and malignant cases or identifying disease subtypes. The demand for faster, more accurate pathology workflows is accelerating adoption, positioning this segment as one of the major growth drivers of the AI pathology market. Automated Image Analysis – Largest Share, Moderate Growth Automated digital image analysis systems currently hold the largest share of the AI pathology market. These platforms automate repetitive slide-analysis tasks such as cell counting, tissue segmentation, and biomarker quantification. While this segment remains dominant in revenue share due to widespread adoption, its growth rate has slowed compared to the emerging predictive and classification-based AI tools. In essence, automated image analysis provides the established backbone of the market but is expanding at a steadier pace. Which application segment is expanding the fastest in the AI-Powered Pathology Market? Diagnostic Centers – Fastest Growth Independent diagnostic centers and pathology laboratories are adopting AI technologies at the fastest rate. The integration of AI into diagnostic workflows helps reduce turnaround times and enhances service differentiation. As these facilities increasingly leverage AI to handle high volumes and improve accuracy, they represent the most rapidly expanding end-use segment in the market. Laboratories & Research Institutes – Steady Growth Hospital-affiliated laboratories and research institutions are gradually integrating AI pathology solutions for high-throughput analysis, biomarker discovery, and clinical trial support. Growth in this segment remains steady, driven by innovation and R&D investments, although adoption is more measured compared to commercial diagnostic centers due to existing in-house expertise and infrastructure. Hospitals – Largest Share, Slower Growth Hospitals and clinics continue to account for the largest share of the AI pathology market, as the majority of biopsy and pathology tests originate from hospital-based laboratories. AI tools are extensively used to improve operational efficiency and reduce workload pressures. However, because hospital pathology departments are typically well established, their growth trajectory is slower than that of independent centers. Hospitals thus maintain market dominance in terms of value but exhibit more moderate expansion. Key Companies: Indica Labs Aignostics Deep Bio Mindpeak Paige AI DoMore Diagnostics Visiopharm Sonrai Analytics Stratipath ArteraAI PathAI Proscia Aiforia Hologic Dipath Which region dominates the AI Powered Pathology Market? The AI-Powered Pathology Market is currently dominated by North America, which accounts for the largest share of global revenue. This dominance is attributed to the region's early adoption of digital pathology solutions, robust healthcare infrastructure, and growing investments in AI-driven diagnostic technologies. The United States leads the market, supported by favorable regulatory frameworks such as FDA approvals for AI pathology systems and the strong presence of key industry players including Paige AI, PathAI, and Proscia. Moreover, large-scale cancer research programs, academic collaborations, and precision medicine initiatives across the U.S. and Canada continue to accelerate the integration of AI into pathology workflows. Purchase Regional Report: https://reports.valuates.com/request/regional/QYRE-Auto-33C18563/Global_AI_Powered_Pathology_Market?utm_source=prnewswire&utm_medium=referral&utm_campaign=ai_powered_pathology_market SUBSCRIPTION We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans. What are some related markets to the AI-Powered Pathology Market? Artificial Intelligence Pathology Diagnosis Market Digital Pathology Market revenue was USD 729 Million in 2022 and is forecast to a readjusted size of USD 1742.7 Million by 2029 with a CAGR of 13.1% during the review period (2023-2029). Digital Pathology Scanner Market was valued at USD 618 Million in the year 2024 and is projected to reach a revised size of USD 1015 Million by 2031, growing at a CAGR of 7.4% during the forecast period. Pathology Diagnosis Devices Market AI in Pathology Market AI Pathology Analysis System Market was valued at USD 103 Million in the year 2024 and is projected to reach a revised size of USD 290 Million by 2031, growing at a CAGR of 16.2% during the forecast period. Laboratory Pathology Service Market Human Digital Pathology Market Veterinary Digital Pathology Market High-speed Pathology Slide Scanner Market Clinical Digital Pathology Market was valued at USD 618 Million in the year 2024 and is projected to reach a revised size of USD 1023 Million by 2031, growing at a CAGR of 7.4% during the forecast period. DISCOVER OUR VISION: VISIT ABOUT US! Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs. Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs. To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources. Contact Us Valuates Reports sales@valuates.com For U.S. Toll-Free Call 1-(315)-215-3225 WhatsApp: +91-9945648335 Explore our blogs & channels: Blog: https://valuatestrends.blogspot.com/ Pinterest: https://in.pinterest.com/valuatesreports/ Twitter: https://twitter.com/valuatesreports Facebook: https://www.facebook.com/valuatesreports/ YouTube: https://www.youtube.com/@valuatesreports6753 Localized content: Korean: https://www.facebook.com/valuateskorean Spanish: https://www.facebook.com/valuatesspanish Japanese: https://www.facebook.com/valuatesjapanese Spanish: https://valuatesreportspanish.blogspot.com/ Korean: https://valuateskorean.blogspot.com/ German: https://valuatesgerman.blogspot.com/ Japanese: https://valuatesreportjapanese.blogspot.com/ This News is brought to you by Qube Mark , your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology. PR Newswire PR Newswire empowers communicators to identify and engage with key influencers, craft and distribute meaningful stories, and measure the financial impact of their efforts. Cision is a leading global provider of earned media software and services to public relations and marketing communications professionals. Your experience on this site will be improved by allowing cookies Cookie Policy
Aignostics Frequently Asked Questions (FAQ)
When was Aignostics founded?
Aignostics was founded in 2018.
Where is Aignostics's headquarters?
Aignostics's headquarters is located at Alt-Moabit 73/73A, Berlin.
What is Aignostics's latest funding round?
Aignostics's latest funding round is Series B.
How much did Aignostics raise?
Aignostics raised a total of $53.94M.
Who are the investors of Aignostics?
Investors of Aignostics include High-Tech Gruenderfonds, VC Fonds Technologie, Boehringer Ingelheim Venture Fund, Wellington Partners, CARMA FUND and 8 more.
Who are Aignostics's competitors?
Competitors of Aignostics include Modella AI and 4 more.
What products does Aignostics offer?
Aignostics's products include R&D and 2 more.
Loading...
Compare Aignostics to Competitors
Aiosyn focuses on developing precision pathology software solutions for the healthcare sector. The company offers AI-powered algorithms that enhance digital pathology workflows and support clinical diagnostics, as well as tools for the identification of pathology-based biomarkers for drug development. Aiosyn primarily serves the healthcare industry, including pathology laboratories and biopharmaceutical companies. It was founded in 2021 and is based in Nijmegen, Netherlands.
Imagene AI specializes in AI-based precision oncology within the healthcare sector, focusing on cancer research and diagnostics. The company offers a SaaS platform that integrates imaging, molecular, and clinical data to support biomarker discovery, trial design, and patient identification. Imagene AI primarily serves the healthcare and oncology research sectors with its diagnostic and treatment solutions. It was founded in 2020 and is based in Miami, Florida.

BioAI focuses on advancing precision medicine through multimodal artificial intelligence within the biopharmaceutical sector. The company offers artificial intelligence (AI) driven services for biomarker discovery, drug target identification, and clinical data sourcing, aiming to enhance drug discovery and clinical development processes. BioAI primarily serves the biopharma industry, leveraging AI to improve disease diagnosis and predict patient responses to therapies. It was founded in 2020 and is based in Manchester, New Hampshire.

Ibex specializes in AI-based cancer diagnostics within the healthcare technology sector. The company offers AI-powered diagnostic solutions that assist pathologists in providing accurate and efficient cancer diagnoses. Its solutions are developed using advanced algorithms and digital workflows to detect cancer with clinical-grade accuracy. It was founded in 2016 and is based in Tel Aviv, Israel.

Nucleai focuses on spatial biology in precision medicine. The company provides artificial intelligence (AI)-powered image analysis applications to pharmaceutical companies and clinicians, enhancing drug development and supporting treatment decisions. It primarily serves the pharmaceutical industry. It was founded in 2018 and is based in Chicago, Illinois.

Deciphex specializes in digital pathology and artificial intelligence in the healthcare and drug development sectors. The company offers platforms and services that aim to improve pathology reporting efficiency and quality, using AI to assist pathologists and streamline the diagnostic process. Deciphex's solutions serve the medical and pharmaceutical industries, with an emphasis on health service delivery and drug development. It was founded in 2017 and is based in Dublin, Ireland.
Loading...

